Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 4
2012 2
2013 7
2014 4
2015 7
2016 6
2017 6
2018 7
2019 9
2020 9
Text availability
Article attribute
Article type
Publication date

Search Results

51 results
Results by year
Filters applied: . Clear all
Page 1
Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma.
Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, Tabbò F, Cartia CF, Passone E, Comunanza V, Ardissone F, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, Riganti C. Salaroglio IC, et al. Among authors: Kopecka J. J Thorac Oncol. 2019 Aug;14(8):1458-1471. doi: 10.1016/j.jtho.2019.03.029. Epub 2019 May 9. J Thorac Oncol. 2019. PMID: 31078776 Free article.
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.
Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R. Riganti C, et al. Among authors: Kopecka J. Oncoimmunology. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018. Oncoimmunology. 2017. PMID: 29399399 Free PMC article.
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, Saponara S, Sorge M, Hattinger CM, Gasco A, Fruttero R, Brancaccio M, Serra M, Stella B, Fattal E, Arpicco S, Riganti C. Gazzano E, et al. Among authors: Kopecka J. Cancer Lett. 2019 Aug 1;456:29-39. doi: 10.1016/j.canlet.2019.04.029. Epub 2019 Apr 29. Cancer Lett. 2019. PMID: 31047947 Free article.
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M, Rubinstein M, Riganti C, Kopecka J. Salaroglio IC, et al. Among authors: Kopecka J. J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0. J Exp Clin Cancer Res. 2018. PMID: 30482226 Free PMC article.
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma.
Buondonno I, Gazzano E, Tavanti E, Chegaev K, Kopecka J, Fanelli M, Rolando B, Fruttero R, Gasco A, Hattinger C, Serra M, Riganti C. Buondonno I, et al. Among authors: Kopecka J. Cell Mol Life Sci. 2019 Feb;76(3):609-625. doi: 10.1007/s00018-018-2967-9. Epub 2018 Nov 14. Cell Mol Life Sci. 2019. PMID: 30430199
HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.
Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Bo MD, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M. Griggio V, et al. Among authors: Kopecka J. Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9. Haematologica. 2020. PMID: 31289209 Free PMC article.
ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.
Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C. Salaroglio IC, et al. Among authors: Kopecka J. Int J Mol Sci. 2019 May 21;20(10):2505. doi: 10.3390/ijms20102505. Int J Mol Sci. 2019. PMID: 31117237 Free PMC article. Review.
51 results
Jump to page
Feedback